Capmatinib (INC280)
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for Capmatinib (INC280), covering 2018-05-24 to 2024-02-08. Get the full timeline:
Most recent: Clinical Trial Update: Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50% [Phase 2]